Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Once-weekly semaglutide in adolescents with obesity

Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, Kelly AS, Mastrandrea LD, Sørrig R, Arslanian S. New England Journal of Medicine 2022

Document identifier
CEI-BR-119
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, Kelly AS, Mastrandrea LD, Sørrig R, Arslanian S
Title
Once-weekly semaglutide in adolescents with obesity
Source
New England Journal of Medicine
Year
2022
Volume, issue, pages
387(24):2245–2257
Digital object identifier
10.1056/NEJMoa2208601
PubMed identifier
36322838
Record type
Journal article
Institute identifier
CEI-BR-119

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: SemaglutideCompound monograph
Trial abstract: STEP-TEENSTrial abstract
Synthesis: Incretin receptor agonists in adolescentsEvidence synthesis
3 citing documents.

§1.3Subject tags

semaglutide adolescents STEP

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.